Endo International (ENDP) Tops Q2 EPS by 22c, Lifts FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Endo Reports Second-Quarter 2018 Financial Results
August 8, 2018 7:00 AM EDTDUBLIN, Aug. 8, 2018 /PRNewswire/ --
Second-quarter 2018 revenues of $715 million compared to second-quarter 2017 revenues of $876 million Second-quarter 2018 XIAFLEX® franchise revenues increased 27 percent versus second-quarter 2017 to $64 million Second-quarter 2018 Sterile Injectables revenues increased 21 percent versus second-quarter 2017 to $218 million Entered exclusive licensing agreement with Nevakar for the development of five 505(b)(2) injectable products Company raises 2018 financial guidance Phase 3 trials for collagenase clostridium histolyticum (CCH) for the treatment of cellulite now expected to have... More